Virtus ETF Advisers’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-18,916
| Closed | -$77.2K | – | 488 |
|
|
2023
Q1 | $77.2K | Sell |
18,916
-7,265
| -28% | -$29.6K | 0.04% | 389 |
|
|
2022
Q4 | $131K | Buy |
26,181
+17,854
| +214% | +$89.6K | 0.07% | 388 |
|
|
2022
Q3 | $109K | Buy |
8,327
+64
| +0.8% | +$838 | 0.04% | 411 |
|
|
2022
Q2 | $106K | Sell |
8,263
-519
| -6% | -$6.66K | 0.04% | 418 |
|
|
2022
Q1 | $134K | Sell |
8,782
-519
| -6% | -$7.92K | 0.06% | 245 |
|
|
2021
Q4 | $165K | Sell |
9,301
-1,623
| -15% | -$28.8K | 0.06% | 311 |
|
|
2021
Q3 | $230K | Sell |
10,924
-577
| -5% | -$12.1K | 0.1% | 230 |
|
|
2021
Q2 | $227K | Buy |
11,501
+627
| +6% | +$12.4K | 0.09% | 257 |
|
|
2021
Q1 | $316K | Buy |
10,874
+189
| +2% | +$5.49K | 0.13% | 231 |
|
|
2020
Q4 | $324K | Sell |
10,685
-4,195
| -28% | -$127K | 0.13% | 190 |
|
|
2020
Q3 | $237K | Sell |
14,880
-2,033
| -12% | -$32.4K | 0.12% | 277 |
|
|
2020
Q2 | $334K | Buy |
+16,913
| New | +$334K | 0.16% | 283 |
|